Unknown PHASE2 INTERVENTIONAL 1-arm NCT05869162

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

A Phase II, Open-Label, Single-Arm, Multicenter Study of Efficacy and Safety of SY-3505 in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Who Have Progressed On or Are Intolerant to Second-Generation ALK TKI

Sponsor: Shouyao Holdings (Beijing) Co. LTD

Conditions Non-small-cell Lung Carcinoma

Interventions SY-3505

Updated 5 times since 2023 Last updated: Aug 24, 2023 Started: Jun 30, 2023 Primary completion: Jun 10, 2025 Completion: Jun 10, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-small-cell Lung Carcinoma, this trial is ongoing. The trial is conducted by Shouyao Holdings (Beijing) Co. LTD and has accumulated 5 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Jul 2025 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Jul 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Sep 2023 — Jul 2024 [monthly]

Recruiting PHASE2
Jun 2023 — Sep 2023 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shouyao Holdings (Beijing) Co. LTD

Data source: Shouyao Holdings (Beijing) Co. LTD

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China